Clinical characteristics of patients with AML
Patient no. . | Sex . | Age, y . | FAB classification . | Cytogenetics . | Treatment . | Allogeneic SCT . | Remission . |
|---|---|---|---|---|---|---|---|
| 1 | F | 44 | M2 | Normal | 2 × IVA, MIDAC | + | CR (5 y) |
| 2 | F | 31 | M3 | t(15;17) | ATRA, 4 × DA | - | CR (8 y) |
| 3 | M | 42 | M1 | 47,XY,+21 | Autologous PBSCT | - | CR (10 mo) |
| 4 | M | 56 | M2 | 47,XY,+8 | 2 × DA, 3 × high-dose AraC | - | CR (1 mo) |
| 5 | F | 56 | M3 | t(15;17) | 1 × AIDA, 2 × HAM | - | CR (1 y) |
| 6 | M | 72 | M5b | t(9;11) | 2 × ICE, 1 × HAM | + | CR (2 y) |
| 7 | F | 37 | RA | Normal | No treatment | - | MDS (RA) |
| 8 | M | 55 | M2 | del 9 | 2 × ICE, 1 × HD AraC | - | CR (1 mo) |
| 9 | F | 20 | M3 | t(15;17) | 4 × ABVD + rad; 1 × AIDA, 1 × IC, 2 × HAM | - | CR (1 mo) |
| 10 | M | 52 | M4 | t(4;11;9) | 2 × ICE, 1 × HAM | - | CR (1 y) |
| 11 | M | 48 | M0 | t(3;14) | 2 × ICE, 1 × HAM | - | Relapse |
| 12 | M | 49 | M1 | t(10;11) | 2 × ICE, 2 × HAM | - | CR (1 y) |
| 13 | M | 69 | M1 | Normal | 2 × ICE, 1 × HAM | - | Relapse (only BM) |
Patient no. . | Sex . | Age, y . | FAB classification . | Cytogenetics . | Treatment . | Allogeneic SCT . | Remission . |
|---|---|---|---|---|---|---|---|
| 1 | F | 44 | M2 | Normal | 2 × IVA, MIDAC | + | CR (5 y) |
| 2 | F | 31 | M3 | t(15;17) | ATRA, 4 × DA | - | CR (8 y) |
| 3 | M | 42 | M1 | 47,XY,+21 | Autologous PBSCT | - | CR (10 mo) |
| 4 | M | 56 | M2 | 47,XY,+8 | 2 × DA, 3 × high-dose AraC | - | CR (1 mo) |
| 5 | F | 56 | M3 | t(15;17) | 1 × AIDA, 2 × HAM | - | CR (1 y) |
| 6 | M | 72 | M5b | t(9;11) | 2 × ICE, 1 × HAM | + | CR (2 y) |
| 7 | F | 37 | RA | Normal | No treatment | - | MDS (RA) |
| 8 | M | 55 | M2 | del 9 | 2 × ICE, 1 × HD AraC | - | CR (1 mo) |
| 9 | F | 20 | M3 | t(15;17) | 4 × ABVD + rad; 1 × AIDA, 1 × IC, 2 × HAM | - | CR (1 mo) |
| 10 | M | 52 | M4 | t(4;11;9) | 2 × ICE, 1 × HAM | - | CR (1 y) |
| 11 | M | 48 | M0 | t(3;14) | 2 × ICE, 1 × HAM | - | Relapse |
| 12 | M | 49 | M1 | t(10;11) | 2 × ICE, 2 × HAM | - | CR (1 y) |
| 13 | M | 69 | M1 | Normal | 2 × ICE, 1 × HAM | - | Relapse (only BM) |
FAB indicates French-American-British; F, female; M, male; RA, refractory anemia; IVA, idarubicin, etoposide, and cytarabine (AraC); DA, daunorubicin and cytarabine; ATRA, all-trans retinoic acid; ICE, idarubicin, cytarabine, and etoposide; HAM, high-dose cytarabine and mitoxantrone; MIDAC, mitroxantrone and intermediate-dose cytarabine; ABVD, doxorubicin bleomycin, vinblastine, and dacarbazine (for Hodgkin disease); PBSCT, peripheral blood stem cell transplantation; AIDA, all-trans retinoic acid and idarubicin; and AraC,.